MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-19-2026
DarioHealth Corp. DPO Ratio 2011-2026 | DRIO
Annual DPO Ratio DarioHealth Corp.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 112 | 55.3 | 43.9 | 75.3 | 83.7 | 179 | 122 | 167 | 175 | 197 | 213 | 114 | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 213 | 43.9 | 128 |
Quarterly DPO Ratio DarioHealth Corp.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 157 | 116 | 92 | - | 77.3 | 99.1 | 73.8 | - | 53 | 37.3 | 49.2 | - | 50 | 67.9 | 105 | - | 76.3 | 112 | 136 | - | 152 | 197 | 213 | - | 152 | 114 | 115 | - | 166 | 153 | 168 | - | 154 | 199 | - | - | 254 | 200 | 190 | - | 221 | 218 | 259 | - | 110 | 107 | 140 | - | - | - | 147 | - | 84.1 | 124 | 70.8 | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 259 | 37.3 | 134 |
DPO Ratio of other stocks in the Diagnostics research industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agilent Technologies
A
|
50.1 | $ 115.48 | 0.82 % | $ 35.1 B |  USA |
 |
Centogene N.V.
CNTG
|
120 | - | -6.23 % | $ 30.6 M |  Germany |
 |
Burning Rock Biotech Limited
BNR
|
125 | $ 16.2 | -0.61 % | $ 175 M |  China |
 |
Aspira Women's Health
AWH
|
189 | - | -6.19 % | $ 10.5 M | USA |
 |
Co-Diagnostics
CODX
|
4.24 K | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
Castle Biosciences
CSTL
|
52 | $ 24.84 | -0.84 % | $ 690 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
45.8 | - | - | $ 562 M |  Britain |
 |
BioNano Genomics
BNGO
|
149 | $ 1.2 | 0.84 % | $ 6.53 M | USA |
|
Akumin
AKU
|
21.3 | - | -17.87 % | $ 25.9 M |  Canada |
 |
Charles River Laboratories International
CRL
|
24.5 | $ 173.89 | -0.58 % | $ 8.62 B | USA |
 |
Accelerate Diagnostics
AXDX
|
125 | - | -61.36 % | $ 2.46 M | USA |
 |
DexCom
DXCM
|
67.7 | $ 62.22 | -0.24 % | $ 24.3 B | USA |
 |
Fulgent Genetics
FLGT
|
34.9 | $ 16.82 | 2.31 % | $ 509 M | USA |
 |
Biomerica
BMRA
|
32.4 | $ 2.17 | -0.91 % | $ 4.98 M | USA |
 |
Global Cord Blood Corporation
CO
|
17.7 | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
61.4 | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
780 | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
43.5 | - | 0.12 % | $ 80.1 M | China |
 |
Exact Sciences Corporation
EXAS
|
49.2 | - | - | $ 19.8 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
8.98 | - | - | $ 10.7 B | USA |
 |
DermTech
DMTK
|
47.4 | - | -11.32 % | $ 2.94 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
14.7 | $ 198.02 | 0.17 % | $ 22 B | USA |
 |
Guardant Health
GH
|
48.6 | $ 93.83 | 2.94 % | $ 11.8 B | USA |
 |
Enzo Biochem
ENZ
|
52.3 | - | -8.98 % | $ 14.8 K | USA |
 |
Lantheus Holdings
LNTH
|
23.6 | $ 76.1 | 0.53 % | $ 5.14 B | USA |
 |
Biocept
BIOC
|
56.3 | - | -13.05 % | $ 7.29 M | USA |
 |
Medpace Holdings
MEDP
|
13.3 | $ 498.34 | 1.81 % | $ 14.4 B | USA |
 |
Heska Corporation
HSKA
|
39.7 | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
112 | - | -20.0 % | $ 1.06 M | USA |
 |
Interpace Biosciences
IDXG
|
33 | $ 1.96 | 5.82 % | $ 8.67 M | USA |
 |
Mettler-Toledo International
MTD
|
53.4 | $ 1 259.94 | -1.11 % | $ 26 B |  Schweiz |
 |
ICON Public Limited Company
ICLR
|
6.52 | $ 114.19 | 2.49 % | $ 9.42 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
24.9 | $ 569.55 | 0.87 % | $ 45.8 B | USA |
 |
Neogen Corporation
NEOG
|
62.7 | $ 9.41 | 0.21 % | $ 2.04 B | USA |
 |
Illumina
ILMN
|
56.3 | $ 127.38 | 0.59 % | $ 20.3 B | USA |
 |
IQVIA Holdings
IQV
|
126 | $ 173.26 | 0.5 % | $ 29.8 B | USA |
 |
Pacific Biosciences of California
PACB
|
59.7 | $ 1.34 | -0.74 % | $ 402 M | USA |
 |
QIAGEN N.V.
QGEN
|
50 | - | - | $ 10.6 B |  Niderland |
 |
Motus GI Holdings
MOTS
|
1.72 | - | -34.28 % | $ 263 K |  Israel |
 |
Chembio Diagnostics
CEMI
|
52.5 | - | 0.22 % | $ 16.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
31.5 | $ 273.72 | 0.36 % | $ 22.8 B | USA |
 |
Myriad Genetics
MYGN
|
45.9 | $ 4.75 | 3.49 % | $ 440 M | USA |
 |
Sotera Health Company
SHC
|
46.9 | $ 14.96 | 0.61 % | $ 4.25 B | USA |
 |
NeoGenomics
NEO
|
19.7 | $ 8.0 | 3.23 % | $ 1.02 B | USA |
 |
National Research Corporation
NRC
|
10.1 | $ 17.16 | -1.04 % | $ 384 M | USA |